Immune recovery markers in a double blind clinical trial comparing dolutegravir and raltegravir based regimens as initial therapy (SPRING-2).
Jose-Ramon BlancoBelén AlejosSantiago MorenoPublished in: PloS one (2020)
After comparing DTG and RAL, no differences on immune recovery markers were observed.